Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present preclinical data supporting the ongoing development of DYNE-253, DYNE-245, DYNE-244 and DYNE-255 for the potential treatment of DMD amenable to skipping of exons 53, 45, 44 and 55, respectively, at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting being held September 25-27, 2026, in San Antonio, TX.

GlobeNewsWire • 21 hours ago

Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:

GlobeNewsWire • Sep 2, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Aug 20, 2026

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -

GlobeNewsWire • Jul 29, 2026

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

- Company's third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -

GlobeNewsWire • Jul 28, 2026

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

GlobeNewsWire • Jul 23, 2026

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.

GlobeNewsWire • Jul 21, 2026

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $375,150,000. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,745,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

GlobeNewsWire • Jul 22, 2026

DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Zacks Investment Research • Jul 21, 2026

Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?

Dyne Therapeutics stock briefly jumped Monday after the FDA agreed to review the company's muscular dystrophy drug.

Investors Business Daily • Jul 20, 2026